Medical Prognosis Institute

With leading edge technology based on DNA microarrays our goal is to improve cancer treatment with existing and future drugs and radiation treatment.

Medical Prognosis Institute, Denmark, is currently conducting phase III clinical trials which serve to validate our claims that we will give cancer patients and physicians the necessary insight needed to help make much improved treatment decisions.

Medical Prognosis Institute was established to address the unmet need of patients, care givers and healthcare professionals to use individualized genomic profiling of tumor tissue for determining which cancer patients will benefit from which specific chemotherapy and/or radiation therapy.

The DNA microarray cutting edge technology allows sofar unseen insight into the specific genetic make-up of each specific tumor, which enables the physician to make a more informed decision:

1. Will the patient benefit from chemotherapy, and
2. exactly which of many available anticancer drugs or radiation treatment will be the most effective in each individual case.

Announcements